Silicone breast implant-induced lymphadenopathy: 18 Cases  by Bauer, Philippe R. et al.
lable at ScienceDirect
Respiratory Medicine CME 4 (2011) 126e130Contents lists avaiRespiratory Medicine CME
journal homepage: www.elsevier .com/locate/rmedcCase Report
Silicone breast implant-induced lymphadenopathy: 18 Casesq
Philippe R. Bauer a,*, Bryan J. Krajicek b, Craig E. Daniels a, Sejal S. Shah c, Jay H. Ryu a
a Pulmonary and Critical Care Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
b Pulmonary, Critical Care and Sleep Medicine, Creighton University Medical Center, Omaha, NE, USA
cAnatomic Pathology, Mayo Clinic, Rochester, MN, USAa r t i c l e i n f o
Article history:
Received 12 January 2011
Accepted 17 January 2011
Keywords:
Prosthesis implantations
Breast
Silicone gels
LymphadenopathyAbbreviations: CT, computed tomography; EBUS
sound-guided transbronchial needle aspiration; FDA
tion; FDG-PET/CT, ﬂuorodeoxyglucose positron emi
tomography; H&E, hematoxylin and eosin stain; IQ
lymphadenopathy; MRI, magnetic resonance imag
tomography.
q Institution at which the work was performed: Ma
* Corresponding author. Tel.: þ1 507 284 2957; fax
E-mail addresses: bauer.philippe@mayo.edu (P
creighton.edu (B.J. Krajicek), daniels.craig@mayo.ed
mayo.edu (S.S. Shah), ryu.jay@mayo.edu (J.H. Ryu).
1755-0017/$36.00  2011 Elsevier Ltd. All rights rese
doi:10.1016/j.rmedc.2011.01.001a b s t r a c t
Background: There is renewed concern regarding the adverse effects of silicone breast implants, particu-
larly regarding implant rupture. Silicone leak can spread to regional lymph nodes, and remote organs,
sometimes mimicking malignancy. The aim of this study was to determine the clinical and radiologic
features, pathologic ﬁndings, and outcome associated with silicone-induced lymphadenopathy in patients
with silicone breast implants.
Methods: Retrospective review of cases of silicone-induced lymphadenopathy after breast implant
encountered at Mayo Clinic Rochester between 1998 and 2008.
Results: We identiﬁed 18 cases of silicone-induced lymphadenopathy (axillary, supraclavicular, internal
mammary, and mediastinal). Fifteen patients had breast reconstruction and 3 breast augmentation. Most
patients experienced symptoms. One patient had pulmonary opacities, retroperitoneal lymphadenopathy,
hypercalcemia, and conﬁrmed silicone in the thyroid, and the omentum. Imaging included mammography,
chest CT, breast MRI and PET scan. Lymph node biopsies and/or breast implant removal conﬁrmed the
diagnosis with characteristic granulomatous inﬂammation and giant cell reaction and/or implant rupture.
Conclusions: Silicone-induced lymphadenopathy can be confused for malignancy or recurrent breast
cancer in patients with breast implants. Silicone breast implant ruptures are relatively uncommon, but
are under-recognized. Silicone usually migrates to the axillary lymph nodes but may migrate to other
lymph nodes as well as extranodal sites.
 2011 Elsevier Ltd. All rights reserved.11. Educational aims
The educational aims of this manuscript are to
 Recognize silicone migration as a cause of lymphadenopathy
in patients with breast implants, not to be confused withmetastatic
cancer, other malignancies or infectious diseases.2. Introduction
Silicone gel implants have been widely used for breast augmen-
tation and reconstruction since the 1960s. However, in 1992, the-TBNA, endobronchial ultra-
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rved.United States Food and Drug Administration (FDA) called a volun-
tary moratorium on the use of silicone gel implants because of
a possible link to connective tissue diseases thus restricting silicone
implant use to breast reconstruction and clinical trials.2 In November
2006, the FDA approved the marketing of silicone gel-ﬁlled breast
implants for breast augmentation in women over 22 years of age.
This approval was based on the conclusion that no convincing
evidence linked silicone implants with connective tissue disease or
cancer.3 Although the number of women who have had breast
implants is not precisely known, national surveys estimate that
greater than 3% of the adult female population has had breast
implantation, and breast augmentation is now the most common
cosmetic surgery performed in the US.4
The exact prevalence of implant rupture remains unclear and
estimates vary widely between 0.3% and 77%5; incidence increases
with implant duration.6 The diagnosis of silicone implant rupture can
be difﬁcult due to the occurrence of “silent” ruptures.7 In fact, the
sensitivity of physical examination for detecting silicone implant
rupture may be as low as 30%8 although the diagnosis is easier when
capsular contracture is present.9 Magnetic resonance imaging (MRI)
techniqueshavemadepossible thediagnosisof previouslyundetected
implant rupture.10 The FDA advises removal of ruptured breast
Table 2
Silicone-induced lymphadenopathy in 18 women based on clinical, radiologic and/
or pathologic features (expressed as number and percentage of the 18 total cases).
Lymph nodes Clinical Radiologic Pathologic Total
Axillary 7 (39) 10 (56) 5 (28) 11 (61)
Internal mammary 0 (0) 7 (39) 0 (0) 7 (39)
Supraclavicular 5 (28) 6 (33) 4 (22) 6 (33)
Mediastinal 0 (0) 5 (28) 3 (17) 5 (28)
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implants is not recommended.12 Silicone leak can remain conﬁned to
the breast or spread to regional lymph nodes13e16 and even to remote
organs where silicone leads to foreign body inﬂammation17e21 and
sometimes mimics neoplastic disorders on imaging studies.22e24
The reintroduction of silicone implants into the US market for
the purpose of breast augmentation is expected to markedly
increase the number of women with silicone implants in the
coming years. The absolute number of complications related to
silicone implants can therefore be expected to rise accordingly.
Though studies have analyzed the pathologic features of silicone
lymphadenopathy and accuracy of imaging modalities in detecting
breast implant rupture, there are relatively few reports that
describe the clinical correlates and the distribution of involved
lymph nodes in patients with ruptured silicone implants. We
attempt to better deﬁne the clinical features, radiologic ﬁndings,
and anatomic distribution of silicone-induced lymphadenopathy in
patients with ruptured silicone breast implants.We describe for the
ﬁrst time the silicone spread to mediastinal lymph nodes and the
use of endobronchial ultrasound (EBUS)-guided biopsy to conﬁrm
this diagnosis.
3. Methods and materials
3.1. Patient selection
Computer-assisted search of electronic medical records at the
Mayo Clinic Rochester from the years 1998e2008 resulted in
identiﬁcation of 20 women with silicone breast implants and
lymphadenopathies consistent with silicone-induced lymphade-
nopathy. Two patients did not authorize the use of their medical
records for research and were excluded from this study. The Mayo
Foundation Institutional Review Board approved this study (IRB #
08-007155).
3.2. Clinical, radiologic and pathologic ﬁndings
Medical records of the remaining 18 women were reviewed to
extract demographics, symptoms at presentation, and clinical
ﬁndings, Radiologic studies were reviewed to identify imaging
features including the distribution pattern of lymphadenopathy.
Pathologic specimens were reviewed (S.S.S.) to conﬁrm the diag-
nosis and to delineate histopathologic features.Table 1
Demographic and clinical features of 18 patients with silicone lymphadenopathy.
Patients characteristics Value
Median age, year (IQR) 56 (48e67)
Female, No (%) 18 (100)
Personal history of breast cancer, No (%) 11 (61)
Breast implants, No (%)
Unilateral
Bilateral
2 (11)
16 (89)
Type of breast surgery
Mastectomy with reconstruction
Augmentation
15 (83)
3 (17)
Symptoms
Breast symptoms (pain, discomfort, contracture,
asymmetry)
Palpable lymph nodes (supraclavicular, axillary)
Constitutional symptoms (fatigue, weight loss,
fever, chills, cough)
None
7 (39)
7 (39)
4 (22)
2 (11)
IQR ¼ interquartile range.3.3. Statistical analysis
The data are summarized as median and interquartile range for
continuous variables, and frequency and percentage for categorical
variables, unless otherwise speciﬁed.
4. Results
4.1. Demographic and clinical features
We identiﬁed 18 women (Table 1), median age 56 year, with
silicone-induced lymphadenopathy (11 axillary, 7 internal
mammary, 6 supraclavicular, 5 mediastinal) (Table 2). Fifteen
patients had undergone mastectomy (14 bilateral) including 11 for
breast cancer, 3 for ﬁbrocystic disease, and 1 for prophylaxis (strong
family history of breast cancer), while 3 had undergone augmen-
tation mammoplasty without mastectomy.
Sixteen patients (89%) experienced symptoms including breast
or chest discomfort, cough, palpable lymphadenopathy, fatigue,
and fever. One patient had hypercalcemia, pulmonary ground glass
opacities, mediastinal, mammary, axillary, and retroperitoneal
lymphadenopathy, with presence of silicone to the axillary lymph
node, thyroid, and the omentum conﬁrmed by histopathology,
showing non-necrotizing granulomatous inﬂammation with
foreign body reaction. Two patients had no symptoms but were
incidentally noted to have bilateral implant rupture on a routine
mammography and right hilar mass on routine chest radiography,
respectively. The suspicion of implant rupture was clinically raised
on initial presentation in only 7 cases (39%), based on the presence
of symptoms in the context of breast implant and clinician
awareness of a possible complication associated with it. The
median time between breast implant and lymph node biopsy and/
or implant removal was 107 months (82e156 months).
4.2. Imaging ﬁndings
Seventeen women (94%) underwent imaging studies (Table 3)
that included mammography with ultrasound, chest computedTable 3
Radiologic and pathologic methods used to diagnose silicone lymphadenop-
athy (LAD) in 18 patients.
Patients, No (%)
Radiologic Methods
Mammography  ultrasound 11 (61)
Chest CT 10 (56)
MRI 10 (56)
PET scan 5 (28)
Pathologic Methods
Surgical lymphadenectomy 5 (28)
CT-guided needle biopsy 3 (17)
Mediastinoscopy 2 (11)
EBUS-TBNA 2 (11)
LAD ¼ lymphadenopathy; CT ¼ computed tomography; MRI ¼ magnetic
resonance imaging; PET ¼ positron emission tomography; EBUS-
TBNA ¼ endobronchial ultrasound-guided transbronchial needle aspiration.
Fig. 2. Chest CT showing a large right hilar mass-like adenopathy measuring
3.1 cm  2.4 cm; Endobronchial ultrasound-guided biopsy conﬁrmed the presence of
silicone by technique of energy-dispersive x-ray microanalysis.
Fig. 1. Chest CT showing mediastinal, prevascular, and aorto-pulmonary window
lymphadenopathy. Also seen are post-operative changes of left mastectomy with
implant irregularity of the implant capsule and extracapsular ﬂuid, indicative of
implant rupture.
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tomography (PET) scanning (Fig. 3). PET scanning was positive in 3
of 5 patients. One remaining patient with axillary lymphadenop-
athy and prior removal of ruptured implant underwent immediate
lymphadenectomy without further imaging.
4.3. Pathologic ﬁndings
Lymph node excisional biopsy (6 patients), EBUS-guided biopsy
(2 patients), mediastinoscopy (2 patients), and/or breast implant
removal (9 patients) conﬁrmed the diagnosis of silicone-induced
lymphadenopathy with characteristic granulomatous inﬂamma-
tion and giant cell reaction (Fig. 4), presence of silicone by electron
microscopic imaging and spectrometrymicroanalysis (7 cases) and/
or evidence of implant rupture. One patient underwent both EBUS-
guided biopsy and mediastinoscopy and the diagnosis was ﬁrmly
established by spectrometry analysis (Figs. 2 and 5). In one patient
who presented with enlarging left lobe of the thyroid, undiagnosed
intra-abdominal intra-thoracic process and hypercalcemia,
thyroidectomy tissue showed exuberant foreign body giant cell
reactionwith granulomas forming multiple nodules ranging in size
from 0.8 to 4.5 cm in greatest dimension and omental tissue frag-
ments showed multinodular ﬁbrosis, chronic inﬂammation, and
occasional giant cell reaction consistent with reaction to silicone.
Thirteen patients (72%) had evidence of implant rupture on
imaging studies. Implant rupturewas identiﬁed bymammography/
ultrasound (5 of 11 patients), chest CT scan (2 of 10 patients) and
MRI (8 of 10 patients). In total, ﬁfteen patients (83%) had conﬁrmed
rupture by imaging and three remained undetermined (evidence of
silicone migration but no evidence of rupture). There was no death
associated with this disorder.
5. Discussion
Although most patients experienced various and non speciﬁc
symptoms, implant rupture was clinically suspected in only 39% ofthe cases initially, based on the existence of symptoms and a past
history of breast implantation. Breast implants are placed for breast
augmentation or reconstruction1 and are made of silicone shells
ﬁlled either with saline or silicone gel. Rupture is a late complica-
tion3 and consists of intracapsular gel (when the gel remains within
the scar tissue capsule surrounding the implant), extracapsular gel
(when the gel moves outside the capsule but remains within the
breast tissue), and migrated gel (when the gel moves beyond the
breast).1 The frequency of asymptomatic rupture of silicone rubber
envelopes is between 0.2 and 4%, and increases with age of the
implant.24 Rupture-free survival is estimated to be 98% at 5 years
and 83%e85% at 10 years for newer implants.5 The silicone gel that
migrates beyond the breast tissue incites inﬂammation and silicone
granuloma formation7 with cell-mediated immune reactivity and T
cell stimulation.25 The presence of lymphadenopathy is often more
a worry for malignancy and in presence of granulomatous inﬂam-
mation, the relationship between a possible implant rupture and
a foreign body reaction is not always established, unless breast
implant rupture is suspected and/or spectrometry microanalysis is
speciﬁcally performed.
In our patients, not only were axillary lymph nodes involved but
silicone migrated also to internal mammary, supraclavicular, and
mediastinal lymph nodes. To the best of our knowledge, this is the
ﬁrst report of conﬁrmed silicone-induced mediastinal lymph node
involvement conﬁrmed by endobronchial ultrasound-guided
transbronchial needle aspiration. The lymphatic drainage of the
breast occurs through three principal routes: the axillary, trans-
pectoral, and internal mammary pathways.26 The axillary lymph
nodes involvement is easily explained by the major lymphatic
drainage of the breast toward the axilla. The intramammary
involvement, ﬁrst reported in 199414 can also be explained by the
other important lymphatic drainage system of the breast.27 Silicone
migration may occur through the same routes but may also spread
in retrograde direction or use other pathways, once the jugular-
subclavian venous conﬂuence has been reached. In case of
obstruction of normal lymphatic ﬂow, collateral pathways open.
These include contralateral internal mammary16 and mediastinal
Fig. 3. FDG-PET/CT imaging showing FDG-avid adenopathy adjacent to the left manubrium, extending inferiorly along the left intramammary chain, subpectoral and superior chest
wall lymph nodes.
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nitis.20,21 The involvement of the thyroid is exceptional but has
been reported previously.18 Of note, silicone migration can occur
due to gel bleed with intact envelope in the absence of implant
rupture.28
The development of lymphadenopathy, particularly in patients
with a history of breast cancer, expectedly raises concern regarding
new or recurrent malignancy. In addition, PET scanning may
demonstrate positive FDG uptake in silicone-induced lymphade-
nopathy and further heighten the suspicion for malignant
disease.29 In patients with silicone breast implant, however, the
possibility of implant rupture or gel bleed with silicone migrationFig. 4. Histopathology of axillary lymph node with non-necrotizing granulomatous
inﬂammation with non-polarizable material and foreign body giant cells containing
vacuoles (H&E, 200x).to the lymph nodes needs to be considered. MRI of the breast is the
imaging study of choice in the diagnosis of silicone breast implant
rupture for most women10 and has the ability to image the entire
implant without the use of ionizing radiation. Alternatively,
mammography, breast ultrasonography, and breast CT may diag-
nose silicone breast implant ruptures when MRI is contraindicated.
Although PET scanning is useful to differentiate benign lesions from
malignant lesions in patients with augmentation mammoplasty
and is superior to the more traditional modalities,30 its role in the
diagnosis of silicone-induced lymphadenopathy remains to be
elucidated. Chest CT is the imaging study of choice for internal
mammary, and mediastinal lymph nodes. CT-guided biopsy for
internal mammary lymph nodes and ﬁberoptic bronchoscopy,
including EBUS-guided transbronchial needle aspiration are useful
for evaluating mediastinal lymph nodes. Spectrometry analysis
can conﬁrm the presence of silicone in the biopsy specimen
and should be requested upon suspicion of silicone-induced
lymphadenopathy.
Limitations of this study include its small sample size and
retrospective nature. Because the patients studied were from
a tertiary referral center, there may also be a component of selec-
tion bias. Despite these limitations, the study does highlight some
important clinical, pathologic, and radiologic features of silicone-
induced lymphadenopathy, a disorder that is likely under
diagnosed.
In conclusion, silicone-induced lymphadenopathy can occur in
patients with breast implants and be confused for recurrence of
breast cancer, other malignancies or benign granulomatous
diseases. Silicone usually migrates to the axillary lymph nodes but
can disseminate to other lymph nodes and extranodal sites causing
various patterns of lymphadenopathy and even extranodal
pathology. Tissue examination is essential in identifying the cause
of lymphadenopathy. When in doubt, diagnosis of silicone-induced
lymphadenopathy can be conﬁrmed by spectrometry analysis.
Fig. 5. Left panel: Electron microscopic (EM) image showing elemental silica (dark black material in upper left corner) in mediastinal lymph node. Right panel: X-Ray microanalysis
verifying elemental silica (Si) from same lymph node: oxygen and carbon peaks (from the resin and sample), silicone peak (from the particle being probed, dark arrow), and
titanium peak (from the support grid).
P.R. Bauer et al. / Respiratory Medicine CME 4 (2011) 126e130130Funding
None.
Disclosure
None.
Statement of interest
The authors declare that they have no actual or potential conﬂict
of interest including no ﬁnancial, personal or other relationships
with other people or organizations within three years of beginning
the submitted work that could inappropriately inﬂuence, or be
perceived to inﬂuence their work.
Acknowledgments
Philippe R. Bauer contributed to conception, design, analysis,
and interpretation of data, and drafting, review, and ﬁnal approval
of the manuscript.
Bryan J. Krajicek contributed to data collection, analysis and
drafting of the manuscript, review and ﬁnal approval.
Craig E. Daniels contributed to analysis and interpretation of
data, and review and ﬁnal approval of the manuscript.
Sejal S. Shah contributed to analysis and interpretation of the
pathology data, and review and ﬁnal approval of the manuscript.
Jay H. Ryu contributed to design of the study, analysis and
interpretation of the data, and review and ﬁnal approval of the
manuscript.
References
1. U.S. Food and Drug Administration. Breast implant, www.fda.gov/
MedicalDevices/ProductsandMedicalProcedures/ImplantsandProsthetics/
BreastImplants/default.htm. Date last updated: May 20, 2009. [accessed
30.11.10].
2. Brown SL, Parmentier CM, Woo EK, Vishnuvajjala RL, Headrick ML. Silicone gel
breast implant adverse event reports to the food and drug administration,
1984e1995. Public Health Rep 1998;113:535e43.
3. U.S. Food and Drug Administration. FDA summary of safety and effectiveness
data, www.accessdata.fda.gov/cdrh_docs/pdf2/P020056b.pdf. Date last upda-
ted: November 16, 2006. [accessed 30.11.10].
4. 2009 report of the 2008 statistics. National clearinghouse of plastic surgery
statistics. Available at, http://www.plasticsurgery.org/Media/stats/2008-US-
cosmetic-reconstructive-plastic-surgery-minimally-invasive-statistics.pdf.
Date last updated: October 4, 2009. [accessed 30.11.10].
5. McLaughlin JK, Lipworth L, Murphy DK, Walker PS. The safety of silicone gel-
ﬁlled breast implants: a review of the epidemiologic evidence. Ann Plast Surg
2007;59:569e80.
6. Marotta JS, Widenhouse CW, Habal MB, Goldberg EP. Silicone gel breast
implant failure and frequency of additional surgeries: analysis of 35 studies
reporting examination of more than 8,000 explants. J Biomed Mater Res
1999;48:354e64.7. Brown SL, Silverman BG, Berg WA. Rupture of silicone-gel breast implants:
causes, sequelae, and diagnosis. Lancet 1997;350:1531e7.
8. Hölmich LR, Fryzek JP, Kjøller K, et al. The diagnosis of silicone breast-implant
rupture: clinical ﬁndings compared with ﬁndings at magnetic resonance
imaging. Ann Plast Surg 2005;54:583e9.
9. Paetau AA, McLaughlin SA, McNeil RB, et al. Capsular contracture and possible
implant rupture: is magnetic resonance imaging useful? Plast Reconstr Surg
2010;125:830e5.
10. Gorczyca DP, Gorczyca SM, Gorczyca KL. The diagnosis of silicone breast
implant rupture. Plast Reconstr Surg 2007;120:49Se61S.
11. Brown SL. Epidemiology of silicone-gel breast implants. Epidemiology
2002;13:S34e9.
12. Rohrich RJ, Clark 3rd CP. Controversy over the silicone gel breast implant:
current status and clinical implications. Tex Med 1993;89:52e8.
13. Truong LD, Cartwright Jr J, Goodman MD, Woznicki D. Silicone lymphade-
nopathy associated with augmentation mammaplasty. Morphologic features of
nine cases. Am J Surg Pathol 1988;12:484e91.
14. Rivero MA, Schwartz DS, Mies C. Silicone lymphadenopathy involving intra-
mammary lymph nodes: a new complication of silicone mammaplasty. Am J
Roentgenol 1994;162:1089e90.
15. Shipchandler TZ, Lorenz RR, McMahon J, Tubbs R. Supraclavicular lymphade-
nopathy due to silicone breast implants. Arch Otolaryngol Head Neck Surg
2007;133:830e2.
16. Kaufman GJ, Sakr RA, Inguenault C, Sarfati I, Nos C, Clough KB. Silicone
migration to the contralateral axillary lymph nodes and breast after highly
cohesive silicone gel implant failure: a case report. Cases J 2009;2:6420.
17. Pﬂeiderer B, Garrido L. Migration and accumulation of silicone in the liver of
women with silicone gel-ﬁlled breast implants. Magn Reson Med
1995;33:8e17.
18. Prebtani AP, Asa SL, Ezzat S. Is granulomatous thyroiditis a complication of
breast implants? Endocr Pathol 2002;13:239e44.
19. Levine RL, Allen TC, Cartwright Jr J, Cagle PT. Silicone thorax due to a ruptured
breast implant. Chest 2005;127:1854e7.
20. Dragu A, Theegarten D, Bach AD, et al. Intrapulmonary and cutaneous silico-
nomas after silent silicone breast implant failure. Breast J 2009;15:496e9.
21. Paredes Vila S, Gonzalez Barcala FJ, Suarez Antelo J, Moldes Rodriguez M,
Abdulkader Nallib I, Valdes Cuadrado L. Pneumonitis caused by silicone gel
following breast implant rupture. Ir J Med Sci 2010;179:141e5.
22. Gil T, Mettanes I, Aman B, et al. Contralateral internal mammary silicone
lymphadenopathy imitates breast cancer metastasis. Ann Plast Surg
2009;63:39e41.
23. Winer LH, Sternberg TH, Lehman R, Ashley FL. Tissue reactions to injected
silicone liquids. A report of three cases. Arch Dermatol 1964;90:588e93.
24. van Diest PJ, Beekman WH, Hage JJ. Pathology of silicone leakage from breast
implants. J Clin Pathol 1998;51:493e7.
25. Smalley DL, Shanklin DR, Hall MF, Stevens MV, Hanissian A. Immunologic
stimulation of T lymphocytes by silica after use of silicone mammary implants.
Faseb J 1995;9:424e7.
26. Sharma A, Fidias P, Hayman LA, Loomis SL, Taber KH, Aquino SL. Patterns of
lymphadenopathy in thoracic malignancies. Radiographics 2004;24:419e34.
27. Eubank WB, Mankoff DA, Vesselle HJ, Eary JF, et al. Detection of locoregional
and distant recurrences in breast cancer patients by using FDG PET. Radio-
graphics 2002;22:5e17.
28. Middleton MS. Magnetic resonance evaluation of breast implants and soft-
tissue silicone. Top Magn Reson Imaging 1998;9:92e137.
29. Hurwitz R. F-18 FDG positron emission tomographic imaging in a case of
ruptured breast implant: inﬂammation or recurrent tumor? Clin Nucl Med
2003;28:755e6.
30. Chen CJ, Lee BF, Yao WJ, Wu PS, Chen WC, Peng SL, et al. A false positive F-FDG
PET/CT scan caused by breast silicone injection. Korean J Radiol 2009;10:194e6.
